MedPath

Zemdri (plazomicin)

These highlights do not include all the information needed to use ZEMDRI™ safely and effectively. See full prescribing information for ZEMDRI. ZEMDRI (plazomicin) injection, for intravenous use Initial U.S. Approval: 2018

Approved
Approval ID

eccf9fd9-53ac-4252-a106-5567b3a82a70

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 27, 2023

Manufacturers
FDA

Cipla USA Inc.

DUNS: 078719707

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Plazomicin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69097-820
Application NumberNDA210303
Product Classification
M
Marketing Category
C73594
G
Generic Name
Plazomicin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 14, 2020
FDA Product Classification

INGREDIENTS (3)

WATERInactive
Code: 059QF0KO0R
Classification: IACT
plazomicinActive
Quantity: 500 mg in 10 mL
Code: LYO9XZ250J
Classification: ACTIB
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Zemdri (plazomicin) - FDA Drug Approval Details